MY008211A in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria and signs of hemolysis

medRxiv 2026 Preprint Open access

Read full text
Authors: Lei Ye, Miao Chen, Hongyan Tong, Bing Han, L Zhang, Hong Chang, X Li, Zengmei Sheng, Chris Yang, Gaixiang Xu, Nina Guo, Yongkai Chen
+12 more Rui Xia, Chunlan Tang, Li Liu, Xiaodan Guo, Yihan Zhang, X Li, Ki Rito, Wilson Chunlin Wang, Geoffrey A. Ross, Carlos de Castro, Chuanrui Xu, F K Zhang
DOI: 10.64898/2026.02.05.26345159
Cited by: 0

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a life–threatening disease characterized by red blood cell (RBC) destruction, blood clots, and impaired bone marrow function. We evaluated the efficacy and safety of 3 dosages of MY008211A, a novel complement factor B inhibitor, for treating PNH. This was a multicenter, open–label, phase 2, dose–finding study of MY008211A among Chinese men and women with complement inhibitor–naive PNH and signs of active hemolysis. Patients with hemoglobin

Fields of Study & Subjects

Complement system in diseases Hemophilia Treatment and Research Hemoglobinopathies and Related Disorders

Publication details

Journal / source
medRxiv
Publication date
6 February 2026
Document type
Preprint